ClinicalTrials.gg
CompletedNCT02543918Updated Jan 6, 2017Results posted

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

A Phase 1 interventional study of Ixekizumab and Boostrix® in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females without compromised immune system
  • Have a of 18 to 32 kilograms per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin-17 (IL-17) antagonists
  • Have participated, within the last 30 days, in a clinical trial involving an product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
  • Have known allergy or to any biologic therapy
  • Past vaccination allergy or Arthus-type hypersensitivity
  • Received a tetanus toxoid-containing vaccine within the last 5 years
  • Severe allergic reaction to Boostrix
  • Allergic to latex
  • Have been immunized with pneumococcal vaccine
  • Known hypogammaglobulinemia
  • History of Guillain-Barre Syndrome
  • Active infectious disease
  • Had a within 1 year prior to screening, or intend to have a live vaccination during the course of the study
  • Evidence of a significant uncontrolled neuropsychiatric disorder -
  • Have a score of 3 on Item 12 of the Quick Inventory of Depressive Symptomatology-Self Report (16 Items) at screening
  • Evidence of infection, , B
  • Had symptomatic herpes zoster within 3 months of screening
  • Women who are lactating
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Ixekizumab + Boostrix® + Pneumovax®23

    Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2. Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2.

    Drug: Ixekizumab · Drug: Boostrix® · Drug: Pneumovax®23

  • Other
    Boostrix® + Pneumovax®23

    Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.

    Drug: Boostrix® · Drug: Pneumovax®23

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations

    Responder to tetanus vaccine defined as a post-vaccination anti-tetanus antibody concentration of \>=1.0 (International Unit (IU) and a \>=1.5-fold increase (50% increase) from baseline if the pre-vaccination concentration is \<=1.0 at baseline OR a \>=2.5-fold increase (150% increase) from baseline if the pre-vaccination concentration is \> 1.0 IU at baseline. Responder to the pneumococcal vaccine is defined as a \>=2-fold increase (100% increase) from baseline in anti-pneumococcal antibody concentrations against \>50% of the 23 serotypes.

    Time frame: Week 6

07

Results

Posted Jan 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneIxekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23
Started4143
Received at least 1 dose of study drug4142
Completed3839
Not completed34
Withdrew: Never treated01
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject11
Withdrew: Adverse event11

Outcome measures

PrimaryPercentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations

Responder to tetanus vaccine defined as a post-vaccination anti-tetanus antibody concentration of \>=1.0 (International Unit (IU) and a \>=1.5-fold increase (50% increase) from baseline if the pre-vaccination concentration is \<=1.0 at baseline OR a \>=2.5-fold increase (150% increase) from baseline if the pre-vaccination concentration is \> 1.0 IU at baseline. Responder to the pneumococcal vaccine is defined as a \>=2-fold increase (100% increase) from baseline in anti-pneumococcal antibody concentrations against \>50% of the 23 serotypes.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations
percentage of participantsIxekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23
Tetanus Vaccine Responders52.651.2
Pneumococcal Vaccine Responders89.590.2
Statistical analysis
  • Ixekizumab + Boostrix® + Pneumovax®23 vs Boostrix® + Pneumovax®23 · Mean difference (final values): 1.4 · 90% CI -16.6 to 19.2
  • Ixekizumab + Boostrix® + Pneumovax®23 vs Boostrix® + Pneumovax®23 · Mean difference (final values): -0.8 · 90% CI -12.9 to 11.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab + Boostrix® + Pneumovax®23—0/41 (0%)1/41 (2.4%)
Boostrix® + Pneumovax®23—0/42 (0%)0/42 (0%)
Most frequent other events
Most frequent other events
EventIxekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23
Vulvovaginal candidiasisInfections and infestations1/190/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ixekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23Total
Mean43.5 ± 12.239.5 ± 10.541.4 ± 11.5
Gender
Gender(Participants)Ixekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23Total
Female191938
Male222446
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23Total
Hispanic or Latino7815
Not Hispanic or Latino343569
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American151732
White242549
More than one race213
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Ixekizumab + Boostrix® + Pneumovax®23Boostrix® + Pneumovax®23Total
United States414384
08

Study locations

3 sites
  • Covance
    Daytona Beach, Florida 32117, United States
  • Covance
    Evansville, Indiana 47710, United States
  • Covance
    Dallas, Texas 75247, United States
09

References and documents

Publications

  • Gomez EV, Bishop JL, Jackson K, Muram TM, Phillips D. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. BioDrugs. 2017 Dec;31(6):545-554. doi: 10.1007/s40259-017-0249-y. PubMed 29116597 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Nov 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2015
First posted
Sep 7, 2015
Start
Sep 2015
Primary completionActual
Nov 2015
CompletionActual
Dec 2015
Results first posted
Jan 6, 2017
Last update
Jan 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02543918
Responsible party
Sponsor
First posted
Sep 7, 2015
Start date
Sep 2015
Primary completion
Nov 2015
Completion
Dec 2015
Results posted
Jan 6, 2017
Last update
Jan 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion